Compare NTLA & TNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | TNC |
|---|---|---|
| Founded | 2014 | 1870 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 2016 | 1994 |
| Metric | NTLA | TNC |
|---|---|---|
| Price | $16.51 | $85.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 2 |
| Target Price | $20.02 | ★ $79.00 |
| AVG Volume (30 Days) | ★ 6.4M | 155.2K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.53% |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | $67,671,000.00 | ★ $1,137,600,000.00 |
| Revenue This Year | N/A | $5.77 |
| Revenue Next Year | $62.75 | $4.95 |
| P/E Ratio | ★ N/A | $8,670.00 |
| Revenue Growth | ★ 16.92 | N/A |
| 52 Week Low | $7.95 | $60.18 |
| 52 Week High | $28.24 | $91.93 |
| Indicator | NTLA | TNC |
|---|---|---|
| Relative Strength Index (RSI) | 59.46 | 47.44 |
| Support Level | $11.73 | $79.08 |
| Resistance Level | $16.93 | $88.53 |
| Average True Range (ATR) | 1.16 | 2.50 |
| MACD | 0.13 | -0.49 |
| Stochastic Oscillator | 56.30 | 26.50 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Tennant Co is engaged in designing, manufacturing and marketing solutions that empower customers to achieve quality cleaning performance, reduce environmental impact and help create a cleaner, safer, healthier world. The Company is committed to creating and commercializing breakthrough, sustainable cleaning innovations to enhance its broad suite of products, including floor maintenance and cleaning equipment, detergent-free and other sustainable cleaning technologies, aftermarket parts and consumables, equipment maintenance and repair service, and asset management solutions. Its products are used in many types of environments, including retail establishments, distribution centers, factories and warehouses, public venues such as arenas and stadiums, office buildings, schools, and more.